MIT Biocide Extension (Type 13): What Changes for Industrial Fluid Manufacturers

Key data

If your company manufactures, formulates or uses cutting fluids, metal treatment fluids or other industrial fluids containing MIT as a biocidal preservative, this decision directly affects you. Commission Implementing Decision (EU) 2026/2127, published on 28 September 2026 and in force since 24 September 2026, prevents a regulatory vacuum that would have forced the withdrawal of these products from the market before science has delivered its final verdict.

The extension is not a definitive renewal: it is a temporary bridge while the European Chemicals Agency (ECHA) and the Commission complete the re-evaluation process of MIT under the Regulation (EU) No 528/2012 on biocidal products.

What does this regulation establish?

The European Commission postpones through this implementing decision the expiry date of the approval of 2-methylisothiazol-3(2H)-one (MIT) for use in biocidal products of product type 13. This product type specifically groups fluids for the treatment of metals and other industrial fluids.

The reason for the extension is technical and procedural: the scientific re-evaluation process of MIT has not been completed within the original timeframe. Without this decision, the approval would have expired automatically, creating a regulatory vacuum that would have forced the withdrawal from the market of all biocidal products with MIT in this category, even without an adverse scientific conclusion.

MIT is a substance with a known sensitizing profile, which means there is already scientific evidence of its ability to cause allergic reactions. This background makes the pending evaluation especially relevant: the result could translate into more restrictive conditions of use, lower concentration limits or, in the worst case scenario, non-renewal of approval.

Economic and operational impact

The immediate impact of this decision is positive in the short term: it avoids the forced interruption of the supply chain and industrial production that depended on MIT as a preservative in type 13 fluids. Without the extension, companies would have had to reformulate their products or stop their marketing abruptly.

However, the operational impact in the medium term presents two scenarios:

• Favorable scenario: The evaluation concludes with renewal of approval, possibly with new conditions of use. Companies must adapt their safety data sheets and labeling if limits or restrictions change.
• Adverse scenario: The evaluation denies renewal or imposes restrictions so severe that MIT use in type 13 becomes unviable. In that case, companies will need to reformulate their products with approved biocidal alternatives, which involves R&D costs, new registrations and possible supply disruptions.

The known sensitizing profile of MIT makes the adverse scenario not dismissible. The companies with the greatest exposure are those that have MIT as the only preservative in their industrial fluid formulations, without alternatives already developed.

Who does it affect?

• Manufacturers of cutting and machining fluids that use MIT as a biocidal preservative in their formulations.
• Formulators of metal treatment fluids (emulsions, semi-synthetics, synthetics) that include MIT in their composition.
• Manufacturers of other industrial fluids of product type 13 that depend on MIT for microbiological control.
• Distributors and marketers of type 13 biocides with MIT on the European market.
• End-user industrial customers (machining shops, metal component manufacturing plants) that purchase and apply these fluids and must be aware of the regulatory status of the products they use.
• Chemical safety and regulatory compliance managers in companies in the metal and manufacturing sector.

Practical example

A cutting fluid manufacturer for the automotive sector formulates its products with MIT as the main biocidal preservative for controlling bacteria and fungi in machining tanks. Its product is registered as a biocidal product of type 13 under Regulation (EU) No 528/2012.

Without Commission Implementing Decision (EU) 2026/2127, MIT approval would have expired and the company would have had to withdraw its product from the European market, with the consequent impact on its industrial customers and its own revenue.

Thanks to the extension, it can continue legally marketing its cutting fluid during the extension period. However, the R&D department and the regulatory compliance manager must now begin evaluating approved biocidal alternatives (such as CMIT/MIT in other proportions or other active substances of type 13), so that if the final evaluation of MIT is adverse, the company has a reformulation solution ready to implement without interruptions in supply to its customers.

What should companies do now?

1. Verify if their products are affected: Check whether the biocides they manufacture, formulate or use contain MIT and are classified as product type 13 under Regulation (EU) No 528/2012.
2. Confirm the validity of their product authorizations: The extension of the active substance approval (MIT) does not replace individual authorizations for each biocidal product. Review that their own product authorizations remain valid.
3. Monitor the MIT re-evaluation process: Follow publications from the ECHA and the EU Official Journal to learn the outcome of the evaluation as soon as it is published, as it may impose new conditions or deny renewal.
4. Initiate an analysis of alternative biocides: Given the known sensitizing profile of MIT and regulatory uncertainty, evaluate which active substances approved for product type 13 are available and whether they are technically viable in current formulations.
5. Update technical and safety documentation: Ensure that safety data sheets (SDS) and product labeling correctly reflect the current regulatory status of MIT during the extension period.
6. Inform industrial customers: Proactively communicate to end users of affected fluids the regulatory situation of MIT, so they can plan in advance for any product change if necessary.

Official source

Consult the complete regulation in official source

Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=CELEX:32026D2127